Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer

Cancer Medicine

Volumn 3, Issue 4, 2014, Pages 855-864

  Illemann, Martin ^a,b   Laerum, Ole Didrik ^a,b   Hasselby, Jane Preuss ^c   Thurison, Tine ^a,b   Høyer Hansen, Gunilla ^a,b   Nielsen, Hans Jørgen ^d   Jørgensen, Lars Nannestad ^e   Olsen, Jesper ^f   Rahr, Hans B ^g   Nielsen, Knud T ^h   Laurberg, Søren ⁱ   Christensen, Ib Jarle ^a,b  

^a FINSEN LABORATORY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c University of Copenhagen   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e BISPEBJERG HOSPITAL   (Denmark)

^f GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

^h RANDERS REGIONAL HOSPITAL   (Denmark)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Colorectal cancer; Immunohistochemistry; Invasion; Survival; uPAR

Indexed keywords

CD68 ANTIGEN; UROKINASE RECEPTOR; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CANCER; FEMALE; HAZARD RATIO; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MYOFIBROBLAST; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; TUMOR ASSOCIATED LEUKOCYTE; ADENOCARCINOMA; BLOOD; CLINICAL TRIAL; COLORECTAL TUMOR; CROSS-SECTIONAL STUDY; IMMUNOLOGY; KAPLAN MEIER METHOD; MACROPHAGE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROGNOSIS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MACROPHAGES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 84929142910     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.242     Document Type: Article

References (25)

1. Peddareddigari, V. G., D. Wang, and R. N. Dubois . 2010. The tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron. 3:149-166.
2. Qian, B. Z., and J. W. Pollard . 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141:39-51.
3. Dano, K., N. Behrendt, G. Hoyer-Hansen, M. Johnsen, L. R. Lund, M. Ploug, et al. 2005. Plasminogen activation and cancer. Thromb. Haemost. 93:676-681.
4. Laufs, S., J. Schumacher, and H. Allgayer . 2006. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 5:1760-1771.
5. Boonstra, M. C., H. W. Verspaget, S. Ganesh, F. J. Kubben, A. L. Vahrmeijer, C. J. van de Velde, et al. 2011. Clinical applications of the urokinase receptor (uPAR) for cancer patients. Curr. Pharm. Des. 17:1890-1910.
6. Alpizar-Alpizar, W., I. J. Christensen, E. Santoni-Rugiu, A.Skarstein, K. Ovrebo, M. Illemann, et al. 2012. Urokinase plasminogen activator receptor on invasive cancer cells: a prognostic factor in distal gastric adenocarcinoma. Int. J. Cancer 131:E329-E336.
7. Laerum, O. D., K. Ovrebo, A. Skarstein, I. J. Christensen, W. Alpizar-Alpizar, L. Helgeland, et al. 2012. Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry. Int. J. Cancer 131:558-569.
8. Pyke, C., E. Ralfkiaer, E. Ronne, G. Hoyer-Hansen, L.Kirkeby, and K. Dano . 1994. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 24:131-138.
9. Illemann, M., N. Bird, A. Majeed, O. D. Laerum, L.R.Lund, K. Dano, et al. 2009. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int. J. Cancer 124:1860-1870.
10. Ganesh, S., C. F. Sier, M. M. Heerding, G. Griffioen, C.B.Lamers, and H. W. Verspaget . 1994. Urokinase receptor and colorectal cancer survival. Lancet 344:401-402.
11. Hoyer-Hansen, G., and I. K. Lund . 2007. Urokinase receptor variants in tissue and body fluids. Adv. Clin. Chem. 44:65-102.
12. Stephens, R. W., H. J. Nielsen, I. J. Christensen, O.Thorlacius-Ussing, S. Sorensen, K. Dano, et al. 1999. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J. Natl Cancer Inst. 91:869-874.
13. Thurison, T., A. F. Lomholt, M. G. Rasch, I. K. Lund, H.J. Nielsen, I. J. Christensen, et al. 2010. A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer. Clin. Chem. 56:1636-1640.
14. Nielsen, H. J., N. Brunner, L. N. Jorgensen, J. Olsen, H.B.Rahr, K. Thygesen, et al. 2011. Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. Scand. J. Gastroenterol. 46:60-69.
15. Ronne, E., N. Behrendt, V. Ellis, M. Ploug, K. Dano, and G. Hoyer-Hansen . 1991. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett. 288:233-236.
16. Ronne, E., G. Hoyer-Hansen, N. Brunner, H. Pedersen, F. Rank, C. K. Osborne, et al. 1995. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res. Treat. 33:199-207.
17. Plesner, T., E. Ralfkiaer, M. Wittrup, H. Johnsen, C. Pyke, T. L. Pedersen, et al. 1994. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am. J.Clin. Pathol. 102:835-841.
18. Harrell, F. E. Jr., K. L. Lee, and D. B. Mark . 1996. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15:361-387.
19. McShane, L. M., D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion, and G. M. Clark . 2006. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res. Treat. 100:229-235.
20. Biswas, S. K., and A. Mantovani . 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11:889-896.
21. Erreni, M., A. Mantovani, and P. Allavena . 2011. Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron. 4:141-154.
22. Balkwill, F., K. A. Charles, and A. Mantovani . 2005. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211-217.
23. Forssell, J., A. Oberg, M. L. Henriksson, R. Stenling, A.Jung, and R. Palmqvist . 2007. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin. Cancer Res. 13:1472-1479.
24. Flatmark, K., E. Borgen, J. M. Nesland, H. Rasmussen, H.O. Johannessen, I. Bukholm, et al. 2011. Disseminated tumour cells as a prognostic biomarker in colorectal cancer. Br. J. Cancer 104:1434-1439.
25. Saelen, M. G., K. Flatmark, S. Folkvord, R. de Wijn, H.Rasmussen, O. Fodstad, et al. 2011. Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination. Angiogenesis 14:481-489.